Andrew G Reaume

Title: Andrew G. Reaume: Inventor in Alzheimer’s Disease Research

Introduction

Andrew G. Reaume is an inventor associated with Waterford, Connecticut, and Cephalon, Inc. His work includes patented research tools designed to support the study of Alzheimer’s disease. He is credited with 4 patents.

Latest Patents

Reaume’s listed patents concern gene-targeted non-human mammals carrying mutations associated with familial Alzheimer’s disease, along with their generational offspring.

One patent describes mammals with genetic modifications involving a familial Alzheimer’s disease presenilin-1 mutation, a human Swedish APP mutation, and a humanized amyloid-beta mutation. The invention also outlines potential uses of these models in identifying compounds for Alzheimer’s disease research and exploring treatment approaches.

Another patent describes gene-targeted mammals, including mice, with a human P264L mutation in the presenilin-1 gene. The disclosed models can be used to screen chemical compounds and investigate Alzheimer’s disease.

Career Highlights

Reaume’s patent work reflects the use of genetically engineered animal models in biomedical research. By incorporating disease-associated mutations into non-human mammals, the inventions provide research platforms for studying Alzheimer’s disease and evaluating candidate compounds.

Collaborations

The supplied information identifies Richard W. Scott and Karen Dorfman as Reaume’s coworkers. It does not specify their roles in the listed patents or describe particular collaborations.

Conclusion

Andrew G. Reaume’s patents focus on genetically targeted animal models that support research into Alzheimer’s disease and the screening of potential therapeutic compounds.